
Rituxan Market, By Indication (Non-Hodgkins Lymphoma (NHL), Mature B-cell Non-Hodgkins Lymphoma, Mature B-cell Acute Leukemia, Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiit
Description
The global Rituxan market, valued at USD 1,584.3 Mn in 2025, is expected to decline steadily to USD 1,082.1 Mn by 2032, exhibiting a negative compound annual growth rate (CAGR) of -5.3% from 2025 to 2032. While Rituxan, a monoclonal antibody targeting CD20 proteins on B-cells, has transformed the treatment of autoimmune disorders and hematological malignancies like rheumatoid arthritis, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia, the market is facing challenges. The expiration of patents and increasing competition from biosimilars are expected to significantly affect the market share of Rituxan during the forecast period.
Market Dynamic
The decline in Rituxan's market is primarily attributed to the rising competition from biosimilars, which offer more affordable alternatives. Despite the drug's successful use in chronic conditions, the high cost of treatment remains a key constraint. Additionally, the potential side effects of Rituxan and the growing number of treatment options are likely to limit its use. However, opportunities exist in expanding Rituxan's indications for diseases such as multiple sclerosis and other autoimmune disorders, alongside new formulations and delivery methods like subcutaneous administration, which could improve patient convenience and mitigate some of the market's challenges.
Key Features of the Study
Market Dynamic
The decline in Rituxan's market is primarily attributed to the rising competition from biosimilars, which offer more affordable alternatives. Despite the drug's successful use in chronic conditions, the high cost of treatment remains a key constraint. Additionally, the potential side effects of Rituxan and the growing number of treatment options are likely to limit its use. However, opportunities exist in expanding Rituxan's indications for diseases such as multiple sclerosis and other autoimmune disorders, alongside new formulations and delivery methods like subcutaneous administration, which could improve patient convenience and mitigate some of the market's challenges.
Key Features of the Study
- This report provides in-depth analysis of the global Rituxan market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Rituxan market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key company covered as a part of this study include Genentech (Part of Roche), Biogen, Chugai Pharmaceutical Co., Ltd., and ZENYAKU KOGYO CO., LTD.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Rituxan market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Rituxan market
- Indication Insights (Revenue, USD Mn, 2020 - 2032)
- Non-Hodgkin’s Lymphoma (NHL)
- Mature B-cell Non-Hodgkin’s Lymphoma
- Mature B-cell Acute Leukemia
- Chronic Lymphocytic Leukemia (CLL)
- Rheumatoid Arthritis (RA)
- Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
- Pemphigus Vulgaris (PV)
- Dosage Forms and Strength Insights (Revenue, USD Mn, 2020 - 2032)
- 100 mg/10 mL (single-use vial)
- 500 mg/50 mL (single-use vial)
- Patient Age Group Insights (Revenue, USD Mn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
- End User Insights (Revenue, USD Mn, 2020 - 2032)
- Hospitals
- Oncology Centers
- Infusion Centers
- Ambulatory Surgical Centers
- Others (Specialty Clinics, etc.)
- Sales Channel Insights (Revenue, USD Mn, 2020 - 2032)
- Online
- Offline
- Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Genentech (Part of Roche)
- Biogen
- Chugai Pharmaceutical Co., Ltd.
- ZENYAKU KOGYO CO., LTD
Table of Contents
165 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Rituxan Market, By Indication
- Global Rituxan Market, By Dosage Forms and Strength
- Global Rituxan Market, By Patient Age Group
- Global Rituxan Market, By End User
- Global Rituxan Market, By Sales Channel
- Global Rituxan Market, By Region
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Industry Trends
- Reimbursement Scenario
- Epidemiology
- Pricing Analysis
- 4. Global Rituxan Market, By Indication, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Non-Hodgkin’s Lymphoma (NHL)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Mature B-cell Non-Hodgkin’s Lymphoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Mature B-cell Acute Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Chronic Lymphocytic Leukemia (CLL)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Rheumatoid Arthritis (RA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Pemphigus Vulgaris (PV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- 5. Global Rituxan Market, By Dosage Forms and Strength, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- 100 mg/10 mL (single-use vial)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- 500 mg/50 mL (single-use vial)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- 6. Global Rituxan Market, By Patient Age Group, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- 7. Global Rituxan Market, By End User, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Oncology Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Infusion Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Others (Specialty Clinics, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- 8. Global Rituxan Market, By Sales Channel, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Online
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Offline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- 9. Global Rituxan Market, By Region, 2020 - 2032, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Dosage Forms and Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Dosage Forms and Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Dosage Forms and Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Dosage Forms and Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Dosage Forms and Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Dosage Forms and Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
- 10. Competitive Landscape
- Genentech (Part of Roche)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Chugai Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ZENYAKU KOGYO CO., LTD
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- 11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
- 12. References and Research Methodology
- References
- Research Methodology
- About us
- *Browse 32 market data tables and 28 figures on ‘Rituxan Market' - Global forecast to 2032
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.